MedMira Inc. is a biotechnology company specializing in rapid diagnostic solutions and technology platforms. The company faces significant financial challenges, evidenced by a gross margin of -26.6% and a net margin of -200.5%, indicating ongoing losses. Additionally, its liquidity ratios are concerning, with a current ratio of only 0.06, suggesting potential difficulties in meeting short-term obligations. While the biotechnology sector holds growth potential, MedMira's current financial health raises red flags for investors.
Loading financial metrics...
Company posted a loss of $-3.0M over the last year, representing 808.2% of revenue.
Operating cash flow has been negative for 3 consecutive quarters, burning $1.2M over the last year.
Exceptional revenue growth of 45.7% YoY demonstrates strong market demand and competitive positioning.
Operating margin expanded by 947.8pp, demonstrating strong operational leverage.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Biotechnology companies of a similar size
Based on 2026-Q3 (April 30, 2026)